our doctor holding Mounjaro pen in Bangkok (Tirzepatide Thailand)
Get Mounjaro in Bangkok, Thailand to support weight loss, fat loss, and diabetic control with expert medical supervision. Mounjaro (Tirzepatide) is a breakthrough GLP-1 and GIP receptor agonist, designed to regulate blood sugar, curb appetite, and promote fat metabolism. At H.U.M. Clinic, a leading weight loss clinic in Bangkok, patients receive personalized consultations to get a prescription and learn the best treatment approach for their needs.
If you’re looking to buy Mounjaro in Thailand or need a refill, it’s essential to consult a licensed doctor to ensure proper dosing and monitoring. As a prescription-only medication, Mounjaro will available soon in Thailand during Q2 of 2025 at H.U.M. Clinic. Please contact us for more information and update about Mounjaro prescription in Bangkok.
our doctor holding Mounjaro pen in Bangkok (Tirzepatide Thailand)
Mounjaro (Tirzepatide) is a breakthrough medication developed by Eli Lilly (USA) that targets both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. It is the first dual-acting incretin therapy approved for Type 2 diabetes and weight loss. With its superior efficacy in lowering blood sugar and promoting significant fat reduction, Mounjaro is revolutionizing diabetes and obesity treatment worldwide.
Mounjaro enhances insulin secretion, reduces appetite, and improves metabolic function. Studies show that it outperforms GLP-1-only drugs like Ozempic and Wegovy, leading to greater HbA1c reduction and more substantial weight loss.
In 2025, Mounjaro will officially be available in Thailand through licensed doctors, hospitals, and clinics. Patients seeking Mounjaro in Bangkok must consult a medical professional for a prescription to ensure safe and effective use.
Obese woman does the research on her phone about mounjaro medication for weight loss
Obesity and diabetes have reached epidemic levels globally, posing serious health risks. In 2022, 1 in 8 people worldwide were living with obesity, and rates have more than doubled since 1990. Thailand is no exception, with rising cases of Type 2 diabetes and metabolic disorders. These conditions significantly increase the risk of heart disease, stroke, and certain cancers, highlighting the urgent need for effective medical interventions.
Many individuals struggle with long-term weight management despite diet and exercise. Hormonal imbalances, insulin resistance, and metabolic dysfunction make it difficult for the body to regulate fat storage and energy use, leading to weight regain.
Mounjaro (Tirzepatide) targets both GIP and GLP-1 receptors, improving insulin sensitivity, appetite control, and fat metabolism. This dual-action therapy provides sustainable weight loss and blood sugar control, offering hope for patients who have struggled with traditional approaches.
Diabetic patient checking for blood sugar after using Mounjaro for a while
Mounjaro (Tirzepatide) is revolutionizing weight loss treatment with its unique dual GIP and GLP-1 receptor activation, providing more effective fat reduction and appetite control than traditional medications. By enhancing metabolism and reducing cravings, Mounjaro helps patients achieve significant, sustainable weight loss. Approved in Thailand in 2024, Mounjaro is expected to be available in Q2-Q3 2025, making it a top choice for those seeking safe and effective medical weight loss in Bangkok.
According to the clinical studies on for weight loss, the SURMOUNT-1 clinical trial, published in The New England Journal of Medicine (NEJM), found that patients taking 15mg of Mounjaro lost up to 22.5% of their body weight over 72 weeks. These results make Mounjaro one of the most effective weight loss medications, surpassing GLP-1-only treatments like Ozempic, Saxenda, and Wegovy.

Table 1: Clinical Study Comparison – Mounjaro vs. other GLP-1 medication for Weight Loss

MedicationAverage Weight Loss (%)Clinical Trial Reference
Mounjaro (Tirzepatide)Up to 22.5%SURMOUNT-1 (NEJM, 2022)
Wegovy (Semaglutide)15-17%STEP Trials (NEJM, 2021)
Ozempic (Semaglutide)10-15%SUSTAIN Trials (Lancet, 2018)
These findings confirm that Mounjaro is more effective than Semaglutide for weight loss and has the potential to help patients lose significant weight safely.
Mounjaro (Tirzepatide) offers a breakthrough solution for Type 2 diabetes management by combining GIP and GLP-1 receptor activation to enhance blood sugar control and insulin sensitivity. Clinical trials show its superior efficacy in lowering HbA1c levels compared to traditional diabetes medications. Approved in Thailand in 2024, Mounjaro will be available in Q2-Q3 2025, providing a powerful option for patients looking to improve diabetic control and overall metabolic health in Bangkok, Thailand.
According to clinical Trials on HbA1c Reduction & Insulin Sensitivity, The SURPASS-2 clinical trial, published in NEJM, compared Mounjaro vs. Ozempic (Semaglutide) in diabetes management. It found that:
  • 📊 Mounjaro 15mg reduced HbA1c by 2.3%, compared to 1.86% with Semaglutide 1mg over 40 weeks.
  • 📉 Patients experienced significant fasting blood sugar reductions, improving overall glycemic control.

Table 2: Clinical Study Comparison – Mounjaro vs. Other Diabetes Treatments

MedicationAverage HbA1c Reduction (%)Clinical Trial Reference
Mounjaro (Tirzepatide) 15mg2.3%SURPASS-2 (NEJM, 2021)
Semaglutide (Ozempic) 1mg1.86%SUSTAIN Trials (Lancet, 2018)
Insulin Degludec (Tresiba)1.94%BEGIN Trials (Diabetes Care, 2012)
These findings confirm that Mounjaro provides superior blood sugar control while also promoting weight loss, making it an excellent choice for Type 2 diabetes management in Thailand.
Mounjaro (Tirzepatide) is a first-in-class medication that activates both GIP and GLP-1 receptors, making it more effective than traditional GLP-1-only treatments. This section explores how Mounjaro compares to Zepbound (another Tirzepatide-based medication) and GLP-1 medications like Ozempic and Wegovy.
Although both contain Tirzepatide, they are marketed differently. In Thailand, Mounjaro is currently available for diabetes, while Zepbound’s approval for weight loss is pending.
  • Mounjaro – FDA-approved for Type 2 diabetes but often prescribed off-label for weight loss.
  • Zepbound – FDA-approved exclusively for obesity and weight loss.
Mounjaro’s dual-incretin mechanism gives it an advantage over Semaglutide-based medications, providing stronger metabolic and fat-loss benefits. Mounjaro activates both:
  • GIP (Glucose-dependent insulinotropic polypeptide) – Enhances insulin release and improves fat metabolism.
  • GLP-1 (Glucagon-like peptide-1) – Regulates appetite, slows digestion, and lowers blood sugar.
  • Mounjaro (Tirzepatide 15mg) – Up to 22.5% weight loss and 2.3% HbA1c reduction.
  • Wegovy (Semaglutide 2.4mg) – Up to 16% weight loss and 1.86% HbA1c reduction.
  • Ozempic (Semaglutide 1mg) – Moderate weight loss and diabetes management.
healthy couple looking for peptide therapy to help with recovery
Mounjaro (Tirzepatide) is the first dual-incretin medication that activates both GIP and GLP-1 receptors, making it more effective for weight loss and diabetes management than traditional GLP-1-only treatments like Ozempic. This section breaks down how Mounjaro works at a biological level, explaining its impact on metabolism, insulin sensitivity, and appetite regulation.
  • Stimulates insulin release after meals.
  • Suppresses glucagon secretion, lowering blood sugar.
  • Delays gastric emptying, leading to prolonged fullness.
  • Reduces appetite, supporting weight loss.
  • Improves insulin sensitivity in muscle, liver, and fat cells.
  • Enhances fat metabolism, reducing fat accumulation.
  • Further suppresses appetite, leading to greater weight loss.
  • Synergizes with GLP-1, making Mounjaro more effective.
Large-scale studies, including SURPASS-1 to SURPASS-5, published in The Lancet and The New England Journal of Medicine (NEJM), found that Mounjaro:
  • 📊 Reduced HbA1c by up to 2.3% (vs. 1.86% with Semaglutide).
  • 📉 Led to 22.5% weight loss in obese patients (vs. 15% with Semaglutide).
  • 🔬 Improved insulin sensitivity, lowering fasting blood sugar significantly.
doctor consultation for medical treatment
Mounjaro (Tirzepatide) is a prescription-only medication in Thailand, meaning patients must consult a licensed doctor before purchasing it. Whether you’re starting treatment or refilling a prescription, it’s essential to follow safe and legal channels to ensure medication authenticity and proper medical supervision.

To obtain Mounjaro in Bangkok at our clinic, follow these steps:

  1. Contact us

    via LINE, WhatsApp, or email to schedule an appointment or place an order.

  2. Doctor Consultation

    Our licensed physician will evaluate your health and determine if Mounjaro is suitable.

  3. Medical Eligibility Check

    Conditions such as Type 2 diabetes, obesity, and metabolic disorders are assessed.

  4. Blood Work (if required)

    Some patients may need baseline lab tests before starting treatment.

  5. Prescription Approval

    A qualified healthcare provider issues the prescription.

  6. Patient Education

    Guidance on dosage, injection technique, and expected results.

If you’re already on Mounjaro therapy, you can refill your prescription at H.U.M. Clinic Bangkok with:
  • Doctor consultations for new and existing users.
  • Hassle-free prescription refills with medical oversight.
  • Temperature-controlled storage & delivery (2-8°C) to maintain medication stability.
why choose us H.U.M. Clinic Bangkok Thailand for your medical care
Mounjaro (Tirzepatide) is available only through licensed clinics and hospitals that source directly from Thailand’s official distributor, Zuellig Pharma. This ensures patients receive authentic, properly stored medication with medical supervision. For those in Bangkok looking for a trusted provider, H.U.M. Clinic offers Mounjaro for weight loss and diabetes treatment with expert consultation.
H.U.M. Clinic, a leading weight loss clinic in Bangkok provides safe and legal access to Mounjaro for patients in Thailand. During your consultation, our expert doctors will:
  • Assess your health profile to determine suitability.
  • Discuss Mounjaro’s benefits, dosage, and potential side effects.
  • Develop a personalized plan for weight loss or diabetes management.
  • Licensed medical clinic with pharmaceutical-grade Mounjaro.
  • Proper storage & handling in temperature-controlled conditions (2-8°C).
  • Comprehensive weight loss & diabetes programs, including IV therapy, peptide therapy, and hormone balancing.
  • Convenient Bangkok location (Asok area at Asoke Intersection).
FAQ and more questions
Can I travel to Thailand and get a Mounjaro prescription as a foreigner?

Yes, foreign patients can receive a Mounjaro prescription in Thailand after consulting with a licensed doctor. Clinics like H.U.M. Clinic provide medical evaluations and prescriptions for both residents and medical tourists seeking weight loss or diabetes treatment.

How do I transition from another GLP-1 medication (Ozempic, Wegovy) to Mounjaro?

Switching from Semaglutide-based medications (Ozempic, Wegovy) to Mounjaro requires a medical consultation. Doctors will adjust your dosage to minimize side effects and ensure a smooth transition based on your current medication, health status, and treatment goals.

Does Mounjaro need to be refrigerated during travel in Thailand?

Yes, Mounjaro must be stored between 2-8°C (35-46°F) to maintain effectiveness. When traveling, use an insulated medical-grade travel cooler. Licensed clinics like H.U.M. Clinic ensure proper cold-chain storage and provide temperature-controlled home delivery.

Does Mounjaro need to be refrigerated during travel in Thailand?

Mounjaro is a once-weekly injection, and prescriptions are typically issued monthly. However, follow-up visits depend on your treatment plan, dosage adjustments, and lab test results. Some clinics, like H.U.M. Clinic, offer remote prescription refills after an initial consultation.

Can I use Mounjaro if I have pre-existing medical conditions?

A doctor will assess your medical history, blood tests, and potential risks before prescribing Mounjaro. It depends on the condition. Mounjaro may not be suitable for individuals with:
A personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Severe gastrointestinal disorders (such as gastroparesis)